Doxorubicin versus Idarubicin in Acute Myeloid Leukemia
Phase 4
Completed
- Conditions
- CancerHaematological Disorders
- Registration Number
- PACTR202309818279236
- Lead Sponsor
- ational Cancer Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 244
Inclusion Criteria
18 years or older
Confirmed AML diagnosis
Exclusion Criteria
Patients with current active second malignancy
AML M3 (Promyelocytic leukemia)
Patients with heart problems (low ejection fraction)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method